Results consistent regardless of pretreatment 25-hydroxyvitamin D levels
TUESDAY, Dec. 13, 2022 (HealthDay News) — Vitamin D supplementation does not prevent statin-associated muscle symptoms (SAMS) or reduce statin discontinuation, according to a study published online Nov. 23 in JAMA Cardiology.
Mark A. Hlatky, M.D., from the Stanford University School of Medicine in California, and colleagues randomly assigned men aged 50 years and older and women aged 55 years and older to daily cholecalciferol (2,000 international units; 1,033 patients) or placebo (1,050 patients).
The researchers found that during 4.8 years of follow-up, SAMS were reported by 31 percent of participants assigned to both groups (adjusted odds ratio, 0.97; 95 percent confidence interval, 0.80 to 1.18; P = 0.78). Statin discontinuation was also similar between the groups (adjusted odds ratio, 1.04; 95 percent confidence interval, 0.80 to 1.35; P = 0.78). Results remained consistent across pretreatment 25-hydroxyvitamin D levels. For participants with vitamin D levels <20 ng/mL and <30 ng/mL, SAMS were reported by 33 and 27 percent of vitamin D-assigned participants, respectively, and 35 and 30 percent of placebo-assigned participants, respectively.
“This suggests that vitamin D lacks a clinically important effect in preventing SAMS,” the authors write.
One author disclosed financial ties to Pharmavite, which provided the vitamin D and placebo for the study.
Nutritional Deficiencies Seen in Youth Taking GLP-1 Receptor Agonists
Maternal Vitamin D Status Linked to Preterm Delivery
Oral Vitamin C Active in Clonal Cytopenia of Undetermined Significance
2009 to 2023 Saw Surge in Probiotic Supplement Use
High-Dose Omega-3 Linked to A-Fib Risk in Patients With High CVD Risk
Docosahexaenoic Acid Supplement Does Not Improve Cognitive Performance
Sugar-Sweetened Beverage, Fruit Juice Intake Linked to Hypertension Risk
Whole Goat Milk Formula Can Reduce Incidence of Atopic Dermatitis in Infants